Vect-Horus

Harnessing TfR1 for Cross-Species Systemic Delivery of siRNAs to Deep Brain Regions Using Single-Domain Antibodies

Emmanuelle BETTENDORF — 2026-05-26T08:02:28Z

Our latest preprint demonstrating the ability of the VECTrans® platform to deliver therapeutics, particularly oligonucleotides, to deep regions of the brain at clinically viable doses has just been published by bioRxiv.

The research by @Guillaume Jacquot and the Vect-Horus team details the unique functions of our technology platform to transport oligonucleotides across the blood-brain barrier and open up new avenues for the treatment of diverse central nervous system disorders.

“Harnessing TfR1 for Cross-Species Systemic Delivery of siRNAs to Deep Brain Regions Using Single-Domain Antibodies”

Vect-Horus appoints Claudia Fromond as new Director of R&D

Emmanuelle BETTENDORF — 2026-03-10T08:10:40Z

We are very pleased to welcome Claudia Fromond to Vect-Horus as our new Director of R&D.

Claudia is a highly regarded pharmacology and translational science leader with extensive experience in R&D. She has successfully overseen first-in-class programs from discovery to Investigational New Drug (IND) application and early clinical development, including a portfolio of seven IND-enabling programs which achieved Phase 1/2 readiness.

“Claudia has a proven track record of successfully managing R&D projects and shaping R&D strategy across numerous modalities. I am confident that her expertise and vision will be key to advancing our technology and expanding our external collaborations,” said Alexandre Tokay, co-founder and CEO of Vect-Horus.

Vect-Horus Enters a CNS-Focused Research Collaboration with OliX Pharmaceuticals

Emmanuelle BETTENDORF — 2026-02-03T14:28:27Z

We are delighted to announce we have entered into a Material Transfer and Evaluation Agreement with OliX Pharmaceuticals, a leading developer of RNAi therapeutics, to initiate a collaboration focused on siRNA delivery for central nervous system (CNS) disorders.

“We are extremely pleased to partner with OliX. This collaboration underscores Vect-Horus' leadership in BBB technology and its commitment to advancing oligonucleotide therapeutics in CNS diseases through strategic partnerships with Pharma and Biotech companies like OliX,” said Alexandre Tokay, CEO of Vect-Horus.

“This partnership has the potential to accelerate the development of innovative treatments and bring renewed hope to patients worldwide, and we are looking forward to a strong collaboration with OliX.”

https://www.globenewswire.com/news-release/2026/02/03/3230746/0/en/Vect-Horus-Enters-a-CNS-Focused-Research-Collaboration-with-OliX-Pharmaceuticals.html

Meet Vect-Horus at Deeptech in Glioblastoma Symposium

Emmanuelle BETTENDORF — 2026-01-13T09:02:03Z

Cédric Malicet, our Oncology Program Director, will be taking part in a panel discussion at the DeepTech in Glioblastoma conference, organized by Paris Saclay Cancer Cluster (PSCC), and taking place January 22 in Villejuif, France.

Cedric will participate in a pitch session entitled “A comprehensive and diverse front against glioblastoma”, along with representatives from Carthera, TheraSonic, Robeauté, Innov'nCare , with the discussion moderated by Professor Ahmed Idbaih .

It takes place during the first session at 9:30am CET.

We look forward to seeing you there!
👉 https://lnkd.in/dEEE9W4G

How blood–brain barrier technology is unleashing CNS therapies

Emmanuelle BETTENDORF — 2025-09-19T13:52:41Z

Nature Research has republished an in-depth article on Vect-Horus in the September issue of Biopharma Dealmakers. The issue focuses on CNS related technologies and therapeutics.
It's well worth having a read, or re-read, of this piece, which outlines our VECTrans platform and its potential to transform the treatment of neurodegenerative disorders.
It also touches on the science and data behind our approach and our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, (…)

- News / page_accueil_3_actus, Science

Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to Organs and Tumors

Emmanuelle BETTENDORF — 2024-04-22T14:25:19Z

Marseille, France, April 22 - Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the publication of a paper in the open-access scientific journal Pharmaceutics Vol 26 (MDPI).

The paper, entitled “LDLR-Mediated Targeting and Productive Uptake of siRNA-Peptide Ligand Conjugates In Vitro and In Vivo”, outlines a study which showed how peptides developed by the company, that target the low-density lipoprotein receptor (LDLR) can support delivery of a model short interfering RNA (siRNA), both in vitro and in vivo. Because the LDLR is differentially expressed in organs and is overexpressed in many cancers including glioblastoma multiforme (GBM) and pancreatic ductal adenocarcinoma (PDAC), the results open new opportunities for delivery to different organs or tumors.

A vector belonging to this family of LDLR-targeting peptides is applied as a theragnostic agent for the diagnostic of GBM and PDAC. The agent, currently in early Phase 1 clinical trials, is co-developed with RadioMedix.

“These results reinforce the potential of vectors to significantly improve the transport and delivery of therapeutic and imaging agents to improve the diagnostic and treatment of cancer and CNS disorders,” said Alexandre Tokay co-founder and CEO of Vect-Horus. “This provides further impetus to our current partnerships and builds on other recent licensing agreements, with Novo Nordisk and Ionis Pharmaceuticals.”

siRNAs are promising therapeutic agents because of their specificity and their potential to modulate gene expression, but their delivery into cells and tissues of interest remains highly challenging due to the lack of efficient and selective delivery systems.

The study identified and optimized a family of peptide-based vectors that target the LDLR. The results validated the LDLR-binding peptides as viable ligands which can trigger efficient delivery of therapeutic oligonucleotides, both in a cellular model and in vivo after systemic administration.

For the full paper, click here

Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases

Emmanuelle BETTENDORF — 2024-01-30T13:24:06Z

Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Ionis Pharmaceuticals, Inc. (Nasdaq: IONS). The agreement provides Ionis with a worldwide, exclusive license for a specified number of targets using Vect-Horus' platform technology ”VECTrans” for systemic delivery of RNA-targeted therapeutics that can cross the blood-brain barrier and address targets in the central nervous system. Ionis has an option to add additional targets to the license. Vect-Horus retains the rights to use its technology, for these specific targets, for all non-RNA-Targeted Medicines.

Under the terms of the agreement, Vect-Horus will receive a double-digit million-dollar upfront payment. Vect-Horus will be eligible to receive development, regulatory and commercial milestone payments and tiered single digit royalties on annual product sales.

“We are extremely pleased to partner with Ionis, a pioneer in RNA-targeted medicines, to tackle one of the toughest problems in RNA therapeutics, systemic delivery of therapeutics across the blood-brain barrier,” said Alexandre Tokay co-founder and CEO of Vect-Horus. “This license is aligned with our strategy of using our technology to deliver drug payloads, such as RNA-targeted therapeutics, to the brain and other tissues. We hope that combining our technology with Ionis' industry-leading RNA-targeted drug platform will enable the creation of innovative medicines for a variety of neurological diseases.”

"With a proven track record of delivering first-in-class disease modifying medicines for serious neurological diseases, we believe we are well positioned to tackle the next frontier of delivery of neurology medicines across the blood-brain barrier," said Eric E. Swayze, Ph.D., Ionis' executive vice president of research. "Vect-Horus' promising technology represents a strategic addition to our industry-leading RNA technologies, providing us with the potential to bring systemically-delivered medicines to patients in need of treatment options across both rare and common neurological diseases.”